| Prader-Willi Syndrome
Genotropin vs Vykat
Side-by-side clinical, coverage, and cost comparison for prader-willi syndrome.Deep comparison between: Genotropin vs Vykat Xr with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVykat Xr has a higher rate of injection site reactions vs Genotropin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vykat Xr but not Genotropin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Genotropin
Vykat Xr
At A Glance
SC injection
6-7 times weekly
Recombinant human growth hormone
Oral
Daily
Insulin secretion inhibitor
Indications
- Somatotropin deficiency
- Prader-Willi Syndrome
- Growth failure
- Turner Syndrome
- Growth Disorders
- Prader-Willi Syndrome
Dosing
Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.
Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.
Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.
Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.
Prader-Willi Syndrome Administer once daily orally; starting dosage 25-150 mg based on body weight with titration every 2 weeks; target maintenance dose 75-525 mg/day; maximum 5.8 mg/kg/day or 525 mg/day; swallow tablets whole without splitting, crushing, or chewing.
Contraindications
- Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Active malignancy
- Known hypersensitivity to somatropin or any excipient
- Active proliferative or severe non-proliferative diabetic retinopathy
- Closed epiphyses (for growth promotion in pediatric patients)
- Known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides
Adverse Reactions
Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)
Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, otitis media and cardiovascular disorders in Turner syndrome, pancreatitis
Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome
Most common (>=10%) Hypertrichosis, edema, hyperglycemia, rash
Serious Hyperglycemia, fluid overload, pulmonary edema, diabetic ketoacidosis, aggression, diabetes mellitus, peripheral edema, lower respiratory tract infection, papular rash (adverse reactions leading to discontinuation)
Pharmacology
Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.
Diazoxide choline is hydrolyzed to diazoxide prior to absorption; diazoxide increases blood glucose primarily by inhibiting insulin release from the pancreas, though the exact mechanism for treating hyperphagia in Prader-Willi syndrome is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Genotropin
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (4/12) · Qty limit (10/12)
Vykat Xr
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Genotropin
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Vykat Xr
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Genotropin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Vykat Xr
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Growth Hormone Deficiency
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Vykat Xr.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GenotropinView full Genotropin profile
Vykat XrView full Vykat Xr profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.